Vaccines for the Prevention ofHuman Papillomavirus Infections

Skin Therapy Letter-Family Practice Edition

关键词: human papillomavirus;    HPV infection;    cervical intraepithelial neoplasia;    HPV vaccine;   

DOI  :  

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Human papillomavirus (HPV) infection is the known cause of almost all cases ofcervical cancer. An understanding of the HPV genome has allowed the development oftwo prophylactic vaccines capable of protecting against both persistent HPV infectionand cervical intraepithelial neoplasia (CIN) with 100% efficacy in fully vaccinatedwomen. The vaccines, manufactured by Merck (Gardasil®, which was approved bythe US FDA in June, 2006) and GlaxoSmithKline (Cervarix®, which will be submittedfor US FDA approval by the end of 2006), both target HPV types 16 and 18, whichtogether account for 70% of cervical cancer. Merck’s vaccine also targets HPV 6 and11, covering =90% of genital warts. These vaccines are highly immunogenic and havean excellent safety profile. HPV vaccines promise to offer an exciting contribution tohealthcare and cancer prevention. However, many questions remain concerning whoto vaccinate, the duration of protection, cost, public acceptance, and the potential forworldwide distribution.

【 授权许可】

Unknown